Updated April 2026

Oxytocin Dosing Protocol

Founder & Lead Researcher · B.S. Civil Engineering, UCLA

Last updated: April 2026

Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.

Share this page

Complete Dosing & Safety Guide for Oxytocin, a Short-Acting Neuropeptide Used in Intranasal and SubQ Research Protocols, covering dosing ranges, reconstitution math, half-life context, side effects, and clinical trial outcomes.

Half-life

3-6 min plasma (IV); ~20 min central (intranasal)

Dose range

Intranasal 10-72 IU; SubQ 100-500 mcg daily

Status

FDA-approved for obstetrics only; investigational otherwise

Quick Reference Dosing Card

Name

Oxytocin

Aliases

OXT; Pitocin; Syntocinon

Name	Oxytocin
Aliases	OXT; Pitocin; Syntocinon
Category	Neuropeptide Hormone / Social Cognition & Neuromodulation
Half-life	3-6 minutes (plasma, IV); ~20 minutes (central, intranasal)
Dosing Frequency	Intranasal: single dose or 1-4x daily; Subcutaneous: once daily
Dose Range	Intranasal: 10-72 IU (~17-120 mcg); Subcutaneous: 100-500 mcg
Titration Schedule	Intranasal: 10-12 IU -> 24 IU -> 48-72 IU; SubQ: 100 mcg -> 200 mcg -> 300 mcg -> 200-500 mcg daily
Common Vial Sizes	2 mg, 5 mg, 10 mg (~6,000 IU)
Route of Administration	Intranasal spray, Subcutaneous injection, IV/IM (obstetric use)
Regulatory Status	FDA-approved for labor induction and postpartum hemorrhage (IV/IM); intranasal and subcutaneous use is investigational.
Developer	Endogenous hormone; synthetic versions by multiple manufacturers (including Pitocin and Syntocinon lines).
Key Stat	A landmark 2005 Nature trial (Kosfeld et al.) found 24 IU intranasal oxytocin increased trust-game behavior, helping launch modern human social-cognition research.

Need peptides? Start with a verified source.

These are PDP's two recommended suppliers, both USA-based, Finnrick-tested, and offering the PEPPAL discount code at checkout when eligible. For a side-by-side breakdown of our two recommended suppliers, read the full comparison.

Featured Suppliers

Single Vial?

Orbitrex Peptides

Need one vial?

Broader selection, single-vial orders, and Finnrick A-rated quality make Orbitrex a strong alternative for one-off purchases or harder-to-find compounds.

Browse Orbitrex Read Orbitrex Review

Our #1 Pick

Peptide Partners

Our #1 supplier

Same-day FedEx 2-Day Air, 59 Finnrick tests, multi-lab coverage, and the best per-mg value make Peptide Partners the recommended source for most buyers.

Shop Peptide Partners Why This Is Our #1 Pick

Affiliate disclosure: some outbound supplier links are affiliate links, and we may earn a commission at no extra cost to you. This supports our free tools and protocol database. Our protocol content and editorial ratings are independent of affiliate relationships.

Need broader sourcing context before choosing a vendor? Compare all COA-verified suppliers in the PepPal supplier rankings.

What Is Oxytocin?

This oxytocin dosing protocol reference covers a naturally occurring nine-amino-acid neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary gland. Often called the bonding hormone, oxytocin has been studied across social cognition, trust, empathy, anxiety regulation, pain modulation, and metabolic function.

Oxytocin dosing protocol visual with vial and clinical reference context.

Structurally, oxytocin is a short chain of nine amino acids (a "nonapeptide") folded into a ring shape, held together by a chemical bond between two specific amino acids in the chain (a disulfide bond between positions 1 and 6). Interestingly, it differs from vasopressin — a hormone that regulates blood pressure and water balance — by only two amino acids. Despite being nearly identical in structure, the two activate different receptor systems and produce very different effects in the body.

Oxytocin has long-standing FDA approval in IV/IM form for obstetric indications (labor induction and postpartum hemorrhage management). Research has expanded into intranasal delivery for social cognition, autism spectrum disorder, PTSD, frontotemporal dementia, obesity, anxiety, and substance-use related endpoints, with mixed results across indications.

Oxytocin is FDA-approved for obstetric use (IV/IM) only. Intranasal and subcutaneous use for social cognition, metabolic, and psychiatric indications remains investigational. Information here is educational and for research reference.

How Oxytocin Works: Central Neuromodulation Through the Oxytocin Receptor System

Oxytocin works through receptors in both the brain and the body. In the brain, it influences social behavior, trust, and stress responses. In the body, it acts on the uterus, heart, and other tissues. The effects aren't one-size-fits-all — they depend on dosing, context, and the specific receptor system involved. Here's how each pathway works.

Mechanistic domains from human and translational oxytocin literature

Oxytocin mechanism section visual in a clinical editorial style.

Oxytocin Receptor (OXTR) in the Central Nervous System

The oxytocin receptor (OXTR) is found in key brain areas involved in fear, memory, reward, and decision-making — including the amygdala, hippocampus, and prefrontal cortex. When oxytocin binds to these receptors, it triggers a signaling cascade (technically: Gq-coupled GPCR activation of the PLC/IP3 pathway) that changes how these brain regions respond. In practical terms, this can reduce threat and anxiety responses in the amygdala and strengthen social-reward signaling in areas linked to dopamine. This is why oxytocin is often studied for trust, bonding, and social anxiety.

OXTR in Peripheral Tissues

Outside the brain, oxytocin receptors are found in the uterus, breast tissue, heart, kidneys, fat tissue, and other organs. This is why oxytocin's most established medical use is in childbirth — it triggers uterine contractions and supports breastfeeding. Newer research also suggests roles in pain relief and tissue repair, which has expanded interest in oxytocin beyond obstetrics. A 2026 JAMA Psychiatry trial reported improved wound-healing metrics when repeated intranasal oxytocin was paired with positive partner interaction.

HPA-Axis Stress Modulation

Oxytocin can help calm your body's stress response. It does this by dialing down the HPA axis — the brain-to-adrenal-gland chain (hypothalamus → pituitary → adrenal glands) that produces cortisol when you're stressed. The catch: this stress-buffering effect works best in supportive social settings. Researchers now describe this as a "social salience" model — oxytocin doesn't simply make you feel good; it amplifies whatever social context you're in, for better or worse.

Vasopressin Cross-Reactivity

Native oxytocin is not perfectly receptor-selective and can engage vasopressin receptors (V1a, V1b, V2), especially at higher exposures. This cross-reactivity informs development of longer-acting, OXTR-selective analogs. At common intranasal research doses (about 18-40 IU), major vasopressin-like adverse signaling appears limited in existing safety datasets.

These pathways position oxytocin as a broad neuromodulator with central and peripheral actions spanning social cognition, stress response, pain signaling, and metabolic endpoints. Variable trial outcomes likely reflect this context-sensitive biology.

Tools for this Protocol

dose to units converter for reconstitution and units.
calculate injection units to lock in syringe draw volume.

Oxytocin Dosing Protocol & Administration Schedule

This table covers two separate oxytocin dosing approaches: intranasal spray (the top four rows) and subcutaneous injection (the bottom four rows). Most clinical trials use intranasal delivery. Subcutaneous protocols are primarily community-derived. Choose the section that matches your route of administration and start at the lowest dose to assess tolerance.

Intranasal — Initial Assessment

Single session

10-12 IU

Frequency: once as needed. 1-2 sprays per nostril when using 4 IU per spray devices; use to establish tolerance.

Intranasal — Standard Research Dose

Ongoing

24 IU

Frequency: once per session, 30-45 minutes before target activity. Most common dose across major trials.

Intranasal — Extended Protocol

4-12 weeks

24 IU

Frequency: 1-2 times daily (morning and afternoon). Chronic dosing schedule used in ASD, PTSD, and FTD studies.

Intranasal — Higher-Dose Research

6-12 weeks

48-72 IU

Frequency: 1-2 times daily. Applied in selected FTD and dose-response trials.

Subcutaneous — Initiation

Weeks 1-2

100 mcg daily

Start low to assess tolerance; roughly equivalent to ~60 IU.

Subcutaneous — Moderate Dose

Weeks 3-4

200 mcg daily

Common community research midpoint.

Subcutaneous — Titration

Weeks 5-6

300 mcg daily

Increase by ~100 mcg every 2 weeks if well tolerated and needed.

Subcutaneous — Maintenance

Weeks 7-12

200-500 mcg daily

Adjust within range by response and tolerability; 500 mcg is typical upper community range.

Phase	Weeks	Dose	Notes
Intranasal — Initial Assessment	Single session	10-12 IU	Frequency: once as needed. 1-2 sprays per nostril when using 4 IU per spray devices; use to establish tolerance.
Intranasal — Standard Research Dose	Ongoing	24 IU	Frequency: once per session, 30-45 minutes before target activity. Most common dose across major trials.
Intranasal — Extended Protocol	4-12 weeks	24 IU	Frequency: 1-2 times daily (morning and afternoon). Chronic dosing schedule used in ASD, PTSD, and FTD studies.
Intranasal — Higher-Dose Research	6-12 weeks	48-72 IU	Frequency: 1-2 times daily. Applied in selected FTD and dose-response trials.
Subcutaneous — Initiation	Weeks 1-2	100 mcg daily	Start low to assess tolerance; roughly equivalent to ~60 IU.
Subcutaneous — Moderate Dose	Weeks 3-4	200 mcg daily	Common community research midpoint.
Subcutaneous — Titration	Weeks 5-6	300 mcg daily	Increase by ~100 mcg every 2 weeks if well tolerated and needed.
Subcutaneous — Maintenance	Weeks 7-12	200-500 mcg daily	Adjust within range by response and tolerability; 500 mcg is typical upper community range.

Titration Notes

Dosing context: Oxytocin does not require a traditional loading phase. Intranasal onset is typically 30-45 minutes, while subcutaneous onset is often 10-20 minutes.

Non-linear response: Dose-response can be non-linear; some central effects may be strongest at lower doses in imaging datasets.

IU to mcg conversion: Oxytocin is standardized around 500-600 IU per mg. A 24 IU dose is approximately 40-48 mcg.

Missed dose guidance: For PRN use, skip catch-up dosing. For daily protocols, resume at the next scheduled dose and avoid doubling.

Timing: Intranasal dosing is typically performed 30-45 minutes before the planned task or session.

Route-specific target: Intranasal administration is used for central receptor targeting, while subcutaneous administration is used mainly for peripheral receptor exposure.

Oxytocin Reconstitution Guide

This table shows how much bacteriostatic (BAC) water to add to common oxytocin vial sizes, what concentration you'll get, and how much liquid to draw for your target dose. Find your vial size on the left, then read across to your dose. Note: smaller BAC water volumes create higher concentrations, which means smaller injection volumes — but they also require more precise syringe measurements.

Vial Size: 2 mg

BAC Water: 1 mL

Concentration: 2,000 mcg/mL

100 mcg: 0.05 mL (5 U)

200 mcg: 0.10 mL (10 U)

300 mcg: 0.15 mL (15 U)

500 mcg: 0.25 mL (25 U)

Vial Size: 5 mg

BAC Water: 2 mL

Concentration: 2,500 mcg/mL

100 mcg: 0.04 mL (4 U)

200 mcg: 0.08 mL (8 U)

300 mcg: 0.12 mL (12 U)

500 mcg: 0.20 mL (20 U)

Vial Size: 5 mg

BAC Water: 2.5 mL

Concentration: 2,000 mcg/mL

100 mcg: 0.05 mL (5 U)

200 mcg: 0.10 mL (10 U)

300 mcg: 0.15 mL (15 U)

500 mcg: 0.25 mL (25 U)

Vial Size: 10 mg

BAC Water: 3 mL

Concentration: 3,333 mcg/mL

100 mcg: 0.03 mL (3 U)

200 mcg: 0.06 mL (6 U)

300 mcg: 0.09 mL (9 U)

500 mcg: 0.15 mL (15 U)

Vial Size: 10 mg

BAC Water: 5 mL

Concentration: 2,000 mcg/mL

100 mcg: 0.05 mL (5 U)

200 mcg: 0.10 mL (10 U)

300 mcg: 0.15 mL (15 U)

500 mcg: 0.25 mL (25 U)

Vial Size	BAC Water Added	Concentration	100 mcg Dose	200 mcg Dose	300 mcg Dose	500 mcg Dose
2 mg	1 mL	2,000 mcg/mL	0.05 mL (5 U)	0.10 mL (10 U)	0.15 mL (15 U)	0.25 mL (25 U)
5 mg	2 mL	2,500 mcg/mL	0.04 mL (4 U)	0.08 mL (8 U)	0.12 mL (12 U)	0.20 mL (20 U)
5 mg	2.5 mL	2,000 mcg/mL	0.05 mL (5 U)	0.10 mL (10 U)	0.15 mL (15 U)	0.25 mL (25 U)
10 mg	3 mL	3,333 mcg/mL	0.03 mL (3 U)	0.06 mL (6 U)	0.09 mL (9 U)	0.15 mL (15 U)
10 mg	5 mL	2,000 mcg/mL	0.05 mL (5 U)	0.10 mL (10 U)	0.15 mL (15 U)	0.25 mL (25 U)

Step-by-Step Reconstitution

Oxytocin reconstitution section visual with clinical protocol context.

Allow the lyophilized oxytocin vial and bacteriostatic water to reach room temperature for about 5-10 minutes.
Swab both vial stoppers with alcohol.
Draw the planned BAC water volume based on your concentration target.
Inject slowly down the inside wall of the peptide vial instead of spraying directly onto the powder.
Let the vial rest briefly; oxytocin dissolves quickly in water.
Gently swirl until fully dissolved and visually clear. Do not shake vigorously.
Label with date and concentration, refrigerate at 2-8C, and use within about 28-30 days.

Need exact syringe units for your vial size and BAC water volume? Use the free PepPal Reconstitution Calculator at https://www.peppal.app/calculator.Open Calculator

Oxytocin Side Effects — What Clinical Research Shows

Intranasal oxytocin has generally shown a favorable tolerability profile in controlled human studies, with many commonly reported effects occurring at rates similar to placebo.

Systematic review signal: A review of 38 randomized trials (N=1,529) found no reliable side effects that clearly separated oxytocin from placebo at 18-40 IU intranasal doses.

Common reported effects: Across longer-duration ASD datasets, frequently reported events included nasal discomfort (14.3%), irritability (9.0%), tiredness (7.2%), diarrhea (4.5%), and skin irritation (4.5%), without statistically significant oxytocin-versus-placebo separation.

Longer-duration data: A 4-week trial in older men using 24 IU twice daily found no major between-group differences in blood pressure, heart rate, urine osmolality, or metabolic biomarkers.

Cardiovascular context: Rapid IV obstetric bolus dosing has known cardiovascular risk signals, but these do not map directly to standard intranasal/subcutaneous research protocols.

Pregnancy consideration: Because oxytocin is uterotonic, non-obstetric intranasal or subcutaneous use is contraindicated in pregnancy unless managed by obstetric clinicians.

Discontinuation rates: In long-duration ASD data (SOARS-B), adverse-event discontinuation was comparable between oxytocin and placebo groups.

For a cross-class safety comparison, see the PepPal Peptide Side Effects Guide.

Oxytocin Clinical Trial Results

Oxytocin has been studied in over 500 registered trials, but results are mixed and highly dependent on context. Early findings (like the landmark 2005 trust study) generated enormous interest, but larger follow-up trials in autism and obesity did not hit their primary endpoints. Newer work on wound healing and dose optimization is more promising. The table below summarizes key studies — pay attention to both positive findings and null results to get the full picture.

Kosfeld et al. (2005), Nature

Behavioral RCT • Single dose

194 healthy males

24 IU intranasal oxytocin increased trust-game transfers without changing non-social risk-taking.

MacDonald et al. (2011)

Systematic review • 38 trials

1,529 participants

No reliable side effects distinguishable from placebo at 18-40 IU intranasal doses.

Cai et al. (2018)

Meta-analysis • 5 RCTs

223 ASD participants

Common adverse events were not statistically associated with oxytocin vs placebo allocation.

Sikich et al. (2021), NEJM SOARS-B

Phase 2 RCT • 24 weeks

290 children/adolescents with ASD

No significant between-group difference on the primary social-withdrawal endpoint.

Rung et al. (2021)

RCT • 4 weeks

103 older males

24 IU BID chronic dosing was safe and well-tolerated on major cardiovascular/metabolic safety markers.

Plessow et al. (2024), NEJM Evidence

Phase 2 RCT • 8 weeks

Adults with obesity

24 IU QID intranasal oxytocin did not reduce body weight versus placebo.

Schneider et al. (2026), JAMA Psychiatry

RCT • 7 days

160 healthy couples

Repeated intranasal oxytocin plus positive partner interaction improved wound healing and reduced cortisol response.

Zhang et al. (2025), Frontiers in Psychiatry

Dose-response meta-analysis • 12 RCTs

498 ASD patients

Higher daily doses (48+ IU/day) were associated with improved social-impairment outcomes versus lower-dose schedules.

Trial	Phase	Duration	Population	Key Result
Kosfeld et al. (2005), Nature	Behavioral RCT	Single dose	194 healthy males	24 IU intranasal oxytocin increased trust-game transfers without changing non-social risk-taking.
MacDonald et al. (2011)	Systematic review	38 trials	1,529 participants	No reliable side effects distinguishable from placebo at 18-40 IU intranasal doses.
Cai et al. (2018)	Meta-analysis	5 RCTs	223 ASD participants	Common adverse events were not statistically associated with oxytocin vs placebo allocation.
Sikich et al. (2021), NEJM SOARS-B	Phase 2 RCT	24 weeks	290 children/adolescents with ASD	No significant between-group difference on the primary social-withdrawal endpoint.
Rung et al. (2021)	RCT	4 weeks	103 older males	24 IU BID chronic dosing was safe and well-tolerated on major cardiovascular/metabolic safety markers.
Plessow et al. (2024), NEJM Evidence	Phase 2 RCT	8 weeks	Adults with obesity	24 IU QID intranasal oxytocin did not reduce body weight versus placebo.
Schneider et al. (2026), JAMA Psychiatry	RCT	7 days	160 healthy couples	Repeated intranasal oxytocin plus positive partner interaction improved wound healing and reduced cortisol response.
Zhang et al. (2025), Frontiers in Psychiatry	Dose-response meta-analysis	12 RCTs	498 ASD patients	Higher daily doses (48+ IU/day) were associated with improved social-impairment outcomes versus lower-dose schedules.

Oxytocin clinical trials section visual with research context.

Ongoing and planned work includes the FOXY trial in frontotemporal dementia (NCT03260920), TNX-2900 in Prader-Willi syndrome, PTSD couples-therapy augmentation studies (NCT06194851), and caregiver stress protocols in dementia contexts (NCT06364228). Across 500+ registered investigations, the field has shifted from a simplistic prosocial framing to a context-dependent social-salience model, with active focus on dose optimization and indication targeting.

Storage & Handling

Temperature

Lyophilized: -20C long-term or 2-8C short-term

Reconstituted: 2-8C refrigeration

Light

Lyophilized: protect from light

Reconstituted: protect from light

Stability

Lyophilized: 2+ years at -20C; 6+ months at 2-8C

Reconstituted: ~28-30 days with BAC water

Handling

Lyophilized: hygroscopic; keep sealed until use

Reconstituted: avoid repeated freeze/thaw; discard if cloudy or particulate

Intranasal spray

Follow manufacturer guidance (often 15-25C room temp or refrigerated)

Discard per manufacturer expiry instructions

State	Temperature	Duration
Temperature	Lyophilized: -20C long-term or 2-8C short-term	Reconstituted: 2-8C refrigeration
Light	Lyophilized: protect from light	Reconstituted: protect from light
Stability	Lyophilized: 2+ years at -20C; 6+ months at 2-8C	Reconstituted: ~28-30 days with BAC water
Handling	Lyophilized: hygroscopic; keep sealed until use	Reconstituted: avoid repeated freeze/thaw; discard if cloudy or particulate
Intranasal spray	Follow manufacturer guidance (often 15-25C room temp or refrigerated)	Discard per manufacturer expiry instructions

Allow cold vials to warm before opening to reduce condensation. Reconstituted solution should remain clear and colorless. If aliquoting for extended storage, thaw each aliquot once.

Oxytocin vs. PT-141 (Bremelanotide) vs. Vasopressin

Oxytocin is often discussed alongside PT-141 (Bremelanotide) and vasopressin because they overlap in research interest areas like intimacy, social behavior, and stress. But they work through completely different receptor systems and have different use cases. This table breaks down the key differences so you can see how each compound fits.

Receptor Targets

Oxytocin: OXTR primary; V1a/V1b/V2 cross-reactivity

PT-141 (Bremelanotide): MC3R and MC4R agonism

Vasopressin (ADH): V1a/V1b/V2 primary; OXTR cross-reactivity

Half-Life

Oxytocin: 3-6 min plasma; ~20 min central intranasal

PT-141 (Bremelanotide): ~2.5 hours

Vasopressin (ADH): ~10-35 min

Dosing Frequency

Oxytocin: Intranasal 1-4x daily or SubQ once daily

PT-141 (Bremelanotide): Typically 1-2x weekly PRN

Vasopressin (ADH): Not used in biohacking peptide protocols

Primary Research Focus

Oxytocin: Social cognition, trust, stress response, ASD/PTSD

PT-141 (Bremelanotide): Sexual desire/arousal

Vasopressin (ADH): Water retention and blood-pressure regulation

Peak Efficacy Signal

Oxytocin: Trust-game improvements and emerging wound-healing outcomes

PT-141 (Bremelanotide): Improved HSDD desire outcomes (Vyleesi program)

Vasopressin (ADH): Hemodynamic and antidiuretic effects

FDA Status

Oxytocin: Approved IV/IM for labor and PPH; other uses investigational

PT-141 (Bremelanotide): FDA-approved (Vyleesi) for premenopausal HSDD

Vasopressin (ADH): FDA-approved (Vasostrict) for vasodilatory shock

Route

Oxytocin: Intranasal, subcutaneous, IV/IM

PT-141 (Bremelanotide): Subcutaneous and intranasal compounded variants

Vasopressin (ADH): Primarily IV clinical use

Unique Advantage

Oxytocin: Broadest evidence base with dual central and peripheral effects

PT-141 (Bremelanotide): Only FDA-approved peptide for sexual desire via CNS pathway

Vasopressin (ADH): Essential ICU hemodynamic utility

Feature	Oxytocin	PT-141 (Bremelanotide)	Vasopressin (ADH)
Receptor Targets	OXTR primary; V1a/V1b/V2 cross-reactivity	MC3R and MC4R agonism	V1a/V1b/V2 primary; OXTR cross-reactivity
Half-Life	3-6 min plasma; ~20 min central intranasal	~2.5 hours	~10-35 min
Dosing Frequency	Intranasal 1-4x daily or SubQ once daily	Typically 1-2x weekly PRN	Not used in biohacking peptide protocols
Primary Research Focus	Social cognition, trust, stress response, ASD/PTSD	Sexual desire/arousal	Water retention and blood-pressure regulation
Peak Efficacy Signal	Trust-game improvements and emerging wound-healing outcomes	Improved HSDD desire outcomes (Vyleesi program)	Hemodynamic and antidiuretic effects
FDA Status	Approved IV/IM for labor and PPH; other uses investigational	FDA-approved (Vyleesi) for premenopausal HSDD	FDA-approved (Vasostrict) for vasodilatory shock
Route	Intranasal, subcutaneous, IV/IM	Subcutaneous and intranasal compounded variants	Primarily IV clinical use
Unique Advantage	Broadest evidence base with dual central and peripheral effects	Only FDA-approved peptide for sexual desire via CNS pathway	Essential ICU hemodynamic utility

Oxytocin and PT-141 are often discussed together for intimacy research, but they work through different receptor systems and have different outcome profiles.

Compounded PT-141 + oxytocin combinations exist in practice, but high-quality randomized combination-trial data is not available.

Vasopressin and oxytocin are structurally similar but can drive different anxiety and cardiovascular patterns.

See the PT-141 Protocol Page for compound-specific guides.

Oxytocin Stacking Protocols

Before combining compounds, read the full stacking safety guide on PepPal.

Community Stack

PT-141 (Bremelanotide) + Oxytocin

Community protocols pair PT-141 and oxytocin for intimacy-oriented research: PT-141 for desire/arousal signaling and oxytocin for social bonding and stress buffering.

No published randomized trial data currently evaluates this specific combination.

See the compound-specific PT-141 protocol for additional context.

View PT-141 protocol

Community Stack

Selank + Oxytocin

Some community protocols pair Selank for anxiolytic support with oxytocin for social-stress modulation.

Evidence for this pairing is community-derived and should be treated as exploratory.

See the compound-specific Selank protocol for additional context.

View Selank protocol

Research Dispatch

Join the mailing list for new protocol and stack releases.

Get notified when new dosing references, stack breakdowns, and calculator-driven research pages go live. No multi-step signup, just the email field.

New protocol pages

Fresh stack breakdowns

Calculator-linked updates

Email signup

Short form. One field. Research updates only.

Frequently Asked Questions — Oxytocin

Q1: What is the standard research dose of oxytocin?

The most commonly studied intranasal dose is 24 IU (about 40-48 mcg), usually delivered as three sprays per nostril from a 4 IU-per-spray device. This is often administered 30-45 minutes before target sessions. Community subcutaneous protocols commonly range from 100-500 mcg daily.

Q2: What is oxytocin's half-life?

Plasma half-life is approximately 3-6 minutes with IV administration. Central half-life after intranasal delivery is around 20 minutes, with behavioral effects that can persist for several hours.

Q3: What effects are usually reported in oxytocin research?

Findings are mixed and context dependent. Reported signals include trust-related behavior changes, social-cognition effects, and stress buffering in supportive contexts. Large ASD and obesity trials have had negative primary endpoints, while newer wound-healing work is emerging.

Q4: How do you reconstitute oxytocin?

Add bacteriostatic water slowly down the vial wall, swirl gently until clear, label concentration/date, and refrigerate at 2-8C. For custom vial and dose math, use https://www.peppal.app/calculator.

Q5: Is oxytocin FDA-approved?

Yes, oxytocin is FDA-approved in IV/IM form for obstetric use (labor induction, labor augmentation, and postpartum hemorrhage management) and appears on the WHO Essential Medicines list for these uses. Intranasal and subcutaneous use for psychiatric, social-cognition, and metabolic goals is investigational.

Q6: What are common side effects of oxytocin?

In intranasal trial datasets, mild nasal irritation, headache, tiredness, and dry mouth are most commonly reported, often at rates similar to placebo.

Q7: How does oxytocin compare to PT-141?

PT-141 acts on melanocortin receptors and primarily targets desire/arousal pathways. Oxytocin acts on OXTR and is studied more for social bonding, stress buffering, and social cognition.

Q8: What vial sizes are common for research oxytocin?

Common lyophilized vial sizes are 2 mg, 5 mg, and 10 mg. Availability changes by supplier and region. For current listings, check https://www.peppal.app/suppliers.

Q9: How much bacteriostatic water should be added to oxytocin?

It depends on vial size and desired syringe precision. Example: 10 mg plus 5 mL yields 2,000 mcg/mL, where 200 mcg equals 10 units on a U-100 syringe. Use https://www.peppal.app/calculator for custom setups.

Q10: What is the maximum dose studied in clinical research?

Intranasal trials have explored high-dose ranges up to 72 IU per administration and flexible daily totals around or above 80 IU/day in selected protocols. Most safety data is concentrated in the 18-72 IU range.

Q11: How should reconstituted oxytocin be stored?

Store reconstituted solution at 2-8C, protect from light, and use within about 28-30 days. Discard if cloudy, discolored, or particulate.

Q12: What is the current state of oxytocin clinical research?

Oxytocin has 535+ registered studies across social cognition, ASD, PTSD, dementia-related endpoints, obesity, wound healing, and stress-related indications. Current work focuses on better dose selection and indication targeting rather than one-size-fits-all use.

Q13: Where can I calculate reconstitution and syringe units?

Use the PepPal calculator for exact dose-to-unit conversions.

Q14: Where can I compare peptide suppliers?

Browse the PepPal supplier directory for current supplier listings.

Sources & Research

Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature, 2005 Link.
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology, 2011 PubMed.
Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine, 2021 NEJM.
Plessow F, Kerem L, Wronski ML, et al. Intranasal Oxytocin for Obesity. NEJM Evidence, 2024 PubMed.
Quintana DS, Lischke A, Grace S, et al. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Molecular Psychiatry, 2021 Nature.
Cai Q, Feng L, Yap KZ. Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder. Psychiatry and Clinical Neurosciences, 2018 PubMed.
Rung JM, Horta M, Tammi EM, et al. Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial. Psychopharmacology, 2021 PubMed.
Schneider E, Hernández C, Brock R, et al. Intranasal Oxytocin and Physical Intimacy for Dermatological Wound Healing and Neuroendocrine Stress. JAMA Psychiatry, 2026 PubMed.
Zhang Y, Zhang X, Huang L. Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders. Frontiers in Psychiatry, 2025 Frontiers.
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews, 2001 PubMed.
Finger EC, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology, 2015 PubMed.
Oxytocin background Wikipedia.

Related Protocols

~2.5 hours

PT-141 (Bremelanotide)

Sexual Function / Melanocortin Agonist

View protocol

~2-10 minutes (plasma)

Selank

Anxiolytic / Neuropeptide

View protocol

~3-5 minutes (plasma)

Semax

Nootropic / Neuropeptide

View protocol

~4 hours (estimated)

BPC-157

Tissue Repair / Peptide

View protocol

~30 minutes (estimated)

KPV

Anti-Inflammatory / alpha-MSH Fragment

View protocol

~15-25 minutes

Melanotan II

Tanning / Sexual Function

View protocol

Convert this protocol into exact units and save it in Pep Pal with the Pep Pal calculator.

Disclaimer

The information on this page is for educational and research reference purposes only. Oxytocin is FDA-approved for specific obstetric indications in IV/IM form. Intranasal and subcutaneous use for psychiatric, social-cognition, metabolic, or wellness applications remains investigational. This is not medical advice.

This page includes affiliate links to vetted peptide suppliers. We may earn a commission at no extra cost to you. Editorial content and protocol methodology remain independent of affiliate relationships.